KDM6A

Loading gene…

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FLT3 ITD + KDM6A LossKDM6A FLT31
Olaparib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Sensitivity Response

Therapy

Cancer

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

FLT3 ITD + KDM6A LossKDM6A FLT31

Olaparib

Acute Myeloid LeukemiaCURATED_BROADER

Predictive

Supports Sensitivity Response

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Bladder Cancer (Columbia University/MSK, Cell 2018) bladder_columbia_msk_2018	unmapped	Ssm	76	130

Cohort

Mapped cancer

Alteration

Affected (n)

Profiled (n)

Frequency (%)

Rank in cohort

Source

Bladder Cancer (Columbia University/MSK, Cell 2018) bladder_columbia_msk_2018

unmapped

Ssm

130

KDM6A Loss5
BET Inhibitor	Malignant Pancreatic Neoplasm	Predictive	D	Supports Sensitivity Response	3	submitted	EID11750 In this study, sensitivity to BET domain inhibitors was tested in KDM6A-null pancreatic cancer cell lines. The BET inhibitor was reported to inhibit the growth of KDM6A null cell lines upon transplant… (full text at CIViC) PMID 29533787 · Andricovich et al., 2018 · Open in CIViC	civic
EZH2 Inhibitor	Malignant Bladder NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	4	submitted	EID11749 In this study, an EZH2 inhibitor was tested for effectiveness against KDM6A-null cancer in mouse and patient-derived xenografts. The growth of KDM6A null tumours was significantly inhibited in the in … (full text at CIViC) PMID 28228601 · Ler et al., 2017 · Open in CIViC	civic
Olaparib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID11034 An array of KDM6 deficient AMP cells showed increased sensitivity to PARP inhibition. In a mouse model xenotransplant with a KDM6A loss of function AMP cell line increased susceptibility to PARP block… (full text at CIViC) Open in CIViC	civic
Olaparib + VenetoclaxCombination	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID11037 Dual targeting of PARP (olipartinib) and BCL2 (venetoclax) was reported to be superior to either PARP or BCL2 inhibition alone in inducing primary AML cell apoptosis, and loss of KDM6A further enhance… (full text at CIViC) Open in CIViC	civic
Venetoclax	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID11036 KDM6A repression was reported to sensitize AML cells to venetoclax. In addition, attenuation of KDM6 was reported to increase mitochondrial activity and intracellular ROS levels and de-reporessed BCL2… (full text at CIViC) Open in CIViC	civic

KDM6A Loss5

BET Inhibitor

Malignant Pancreatic Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID11750

In this study, sensitivity to BET domain inhibitors was tested in KDM6A-null pancreatic cancer cell lines. The BET inhibitor was reported to inhibit the growth of KDM6A null cell lines upon transplant… (full text at CIViC)

PMID 29533787 · Andricovich et al., 2018 · Open in CIViC

civic

EZH2 Inhibitor

Malignant Bladder NeoplasmALIAS

Predictive

Supports Sensitivity Response

submitted

EID11749

In this study, an EZH2 inhibitor was tested for effectiveness against KDM6A-null cancer in mouse and patient-derived xenografts. The growth of KDM6A null tumours was significantly inhibited in the in … (full text at CIViC)

PMID 28228601 · Ler et al., 2017 · Open in CIViC

civic

Olaparib

Acute Myeloid LeukemiaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID11034

An array of KDM6 deficient AMP cells showed increased sensitivity to PARP inhibition. In a mouse model xenotransplant with a KDM6A loss of function AMP cell line increased susceptibility to PARP block… (full text at CIViC)

Open in CIViC

civic

Olaparib + VenetoclaxCombination

Acute Myeloid LeukemiaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID11037

Dual targeting of PARP (olipartinib) and BCL2 (venetoclax) was reported to be superior to either PARP or BCL2 inhibition alone in inducing primary AML cell apoptosis, and loss of KDM6A further enhance… (full text at CIViC)

Open in CIViC

civic

Venetoclax

Acute Myeloid LeukemiaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID11036

KDM6A repression was reported to sensitize AML cells to venetoclax. In addition, attenuation of KDM6 was reported to increase mitochondrial activity and intracellular ROS levels and de-reporessed BCL2… (full text at CIViC)

Open in CIViC

civic

KDM6A R1213*1
(functional)	—UNRESOLVED	Functional	E	Supports Loss Of Function	3	submitted	EID7163 Mutations affecting the functional jumonji C (jmjC) domain of KDM6A inactivates its H3K27 demethylase activity 2 mutations occuring after the R1213* variant, p.C1234Y and p.W1319X, are driver mutation… (full text at CIViC) PMID 22377896 · Mar et al., 2012 · Open in CIViC	civic

KDM6A R1213*1

(functional)

—UNRESOLVED

Functional

Supports Loss Of Function

submitted

EID7163

Mutations affecting the functional jumonji C (jmjC) domain of KDM6A inactivates its H3K27 demethylase activity 2 mutations occuring after the R1213* variant, p.C1234Y and p.W1319X, are driver mutation… (full text at CIViC)

PMID 22377896 · Mar et al., 2012 · Open in CIViC

civic

KDM6A Fusion1
(diagnostic)	Childhood B-cell Acute Lymphoblastic LeukemiaUNRESOLVED	Diagnostic	C	Supports Positive	2	submitted	EID7255 In a cohort of 264 patients with Ph-like B-ALL, one patient with a CRLF2 rearrangement had a PTK2B-KDM6A rearrangement. This fusion partner for PTK2B had not been previously reported. PMID 25207766 · Roberts et al., 2014 · Open in CIViC	civic

KDM6A Fusion1

(diagnostic)

Childhood B-cell Acute Lymphoblastic LeukemiaUNRESOLVED

Diagnostic

Supports Positive

submitted

EID7255

In a cohort of 264 patients with Ph-like B-ALL, one patient with a CRLF2 rearrangement had a PTK2B-KDM6A rearrangement. This fusion partner for PTK2B had not been previously reported.

PMID 25207766 · Roberts et al., 2014 · Open in CIViC

civic

Clinical evidence (8)

Alteration frequency by cohort (188)

Linked publications (0)